Pancreatic Cancer Research

ResearcherUniversity of PittsburghNo recent work listed

James L. Abbruzzese

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9223-2965; OpenAlex author ID A5087376683, A5159603264. Sources: OpenAlex.

Their work

Papers
57 (first author 2, last author 6)
Trials
0
Grants
0
Labs led
2
Collaborators
152
Papers, trials and grants by year

2011: 13 papers · 2012: 15 papers · 2013: 5 papers · 2014: 4 papers · 2015: 4 papers · 2016: 3 papers · 2017: 3 papers · 2018: 2 papers · 2019: 4 papers · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper

Papers 50 of 57

  1. Differential Effects of Dietary Macronutrients on the Development of Oncogenic KRAS-Mediated Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers14112723↗
  2. A case report of microsatellite instability (MSI)-high, HER2 amplified pancreatic adenocarcinoma with central nervous system metastasis. Co-author DOI 10.21037/acr-20-154↗
  3. Genetic variants of the peroxisome proliferator-activated receptor (PPAR) signaling pathway genes and risk of pancreatic cancer. Co-author DOI 10.1002/mc.23208↗
  4. Improved overall survival is still observed in patients receiving delayed adjuvant chemotherapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Co-author DOI 10.1016/j.hpb.2020.03.006↗
  5. Genetic variants in the liver kinase B1-AMP-activated protein kinase pathway genes and pancreatic cancer risk. Co-author DOI 10.1002/mc.23018↗
  6. Measurement of Reactive Oxygen Species by Fluorescent Probes in Pancreatic Cancer Cells. Co-author DOI 10.1007/978-1-4939-8879-2_19↗
  7. Potential functional variants in SMC2 and TP53 in the AURORA pathway genes and risk of pancreatic cancer. Co-author DOI 10.1093/carcin/bgz029↗
  8. Three novel genetic variants in NRF2 signaling pathway genes are associated with pancreatic cancer risk. Co-author DOI 10.1111/cas.14017↗
  9. Genetic variants in the platelet-derived growth factor subunit B gene associated with pancreatic cancer risk. Co-author DOI 10.1002/ijc.31171↗
  10. The Interface of Pancreatic Cancer With Diabetes, Obesity, and Inflammation: Research Gaps and Opportunities: Summary of a National Institute of Diabetes and D… Co-author DOI 10.1097/mpa.0000000000001037↗
  11. Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. Co-author DOI 10.1007/s11605-016-3265-1↗
  12. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. Co-author DOI 10.1093/jnci/djw266↗
  13. Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer. Last author DOI 10.2337/db16-1477↗
  14. RECQ1 A159C Polymorphism Is Associated With Overall Survival of Patients With Resected Pancreatic Cancer: A Replication Study in NRG Oncology Radiation Therapy… Last author DOI 10.1016/j.ijrobp.2015.10.062↗
  15. Clinical Insights Into the Biology and Treatment of Pancreatic Cancer. First author DOI 10.1200/jop.2015.009092↗
  16. The effects of curcumin (diferuloylmethane) on body composition of patients with advanced pancreatic cancer. Co-author DOI 10.18632/oncotarget.7773↗
  17. ABO non-O type as a risk factor for thrombosis in patients with pancreatic cancer. Last author DOI 10.1002/cam4.513↗
  18. Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. Co-author DOI 10.1007/s00280-015-2788-6↗
  19. Cyclopamine-loaded core-cross-linked polymeric micelles enhance radiation response in pancreatic cancer and pancreatic stellate cells. Co-author DOI 10.1021/mp500875f↗
  20. Impacts of new-onset and long-term diabetes on clinical outcome of pancreatic cancer. Last author PMID 26693076↗
  21. Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and surviva… Co-author DOI 10.1007/s11605-013-2412-1↗
  22. Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer. Co-author DOI 10.1088/1478-3975/11/6/065002↗
  23. Transport properties of pancreatic cancer describe gemcitabine delivery and response. Co-author DOI 10.1172/jci73455↗
  24. New option for the initial management of metastatic pancreatic cancer? Co-author DOI 10.1200/jco.2013.54.4155↗
  25. The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer. Co-author DOI 10.1007/s10637-013-9967-2↗
  26. Loss of phosphatase and tensin homolog expression is associated with recurrence and poor prognosis in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.humpath.2012.09.001↗
  27. Clinicopathologic features and prognosis of duodenal adenocarcinoma and comparison with ampullary and pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.humpath.2013.07.030↗
  28. Pancreatic intraepithelial neoplasia and histological changes in non-neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic ductal… Co-author DOI 10.1111/his.12234↗
  29. Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis. Co-author DOI 10.1245/s10434-013-2889-6↗
  30. Association of diabetes and perineural invasion in pancreatic cancer. Co-author DOI 10.1002/cam4.43↗
  31. Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation. Co-author DOI 10.1002/cncr.26243↗
  32. Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcom… Co-author DOI 10.1002/cncr.26651↗
  33. Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with n… Co-author DOI 10.1002/cncr.26717↗
  34. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Co-author DOI 10.1002/cncr.27636↗
  35. DNA mismatch repair network gene polymorphism as a susceptibility factor for pancreatic cancer. Co-author DOI 10.1002/mc.20817↗
  36. The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis. Co-author DOI 10.1007/s00280-011-1705-x↗
  37. Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer. Co-author DOI 10.1007/s11605-011-1748-7↗
  38. Insulin-like growth factor axis gene polymorphisms modify risk of pancreatic cancer. Co-author DOI 10.1016/j.canep.2011.05.013↗
  39. Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative exploration. Co-author DOI 10.1016/j.jamcollsurg.2012.03.024↗
  40. Tumor invasion of muscular vessels predicts poor prognosis in patients with pancreatic ductal adenocarcinoma who have received neoadjuvant therapy and pancreat… Co-author DOI 10.1097/pas.0b013e318240c1c0↗
  41. Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/pas.0b013e31824104c5↗
  42. Overexpression of protein phosphatase 4 correlates with poor prognosis in patients with stage II pancreatic ductal adenocarcinoma. Co-author DOI 10.1158/1055-9965.epi-12-0223↗
  43. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. First author DOI 10.1158/1078-0432.ccr-11-2994↗
  44. Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression. Co-author DOI 10.1186/1756-8722-5-15↗
  45. Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cncr.25483↗
  46. Association of multi-drug resistance gene polymorphisms with pancreatic cancer outcome. Co-author DOI 10.1002/cncr.25510↗
  47. Glucose metabolism gene polymorphisms and clinical outcome in pancreatic cancer. Co-author DOI 10.1002/cncr.25612↗
  48. Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial. Co-author DOI 10.1007/s00280-011-1601-4↗
  49. A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. Last author DOI 10.1007/s10637-010-9386-6↗
  50. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. Co-author DOI 10.1093/jnci/djr243↗

Closest collaborators

The 25 strongest of 152 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Robert A. Wolff · 20 shared papers, 2011–2017 · strength 0.61
  2. Jason B. Fleming · 20 shared papers, 2011–2017 · strength 0.60
  3. Matthew H. G. Katz · 18 shared papers, 2012–2017 · strength 0.57
  4. Huamin Wang · 18 shared papers, 2011–2017 · strength 0.56
  5. Donghui Li · 13 shared papers, 2011–2017 · strength 0.55
  6. Jeffrey E. Lee · 17 shared papers, 2011–2017 · strength 0.51
  7. Gauri Rajani Varadhachary · 15 shared papers, 2011–2017 · strength 0.44
  8. Peter W. T. Pisters · 13 shared papers, 2012–2017 · strength 0.40
  9. Qingyi Wei · 4 shared papers, 2018–2020 · strength 0.39
  10. Christopher H. Crane · 11 shared papers, 2011–2017 · strength 0.35
  11. Craig D. Logsdon · 5 shared papers, 2011–2022 · strength 0.28
  12. Kenneth R. Hess · 7 shared papers, 2011–2014 · strength 0.28
  13. Yongde Luo · 2 shared papers, 2019–2022 · strength 0.28
  14. Weiqin Lu · 2 shared papers, 2019–2022 · strength 0.28
  15. Bensong Duan · 3 shared papers, 2018–2019 · strength 0.26
  16. Milind M. Javle · 8 shared papers, 2011–2017 · strength 0.26
  17. Niharika B. Mettu · 2 shared papers, 2016–2021 · strength 0.24
  18. Hua Wang · 8 shared papers, 2011–2013 · strength 0.24
  19. David R. Fogelman · 6 shared papers, 2011–2017 · strength 0.21
  20. Ping Chang · 5 shared papers, 2011–2016 · strength 0.21
  21. Xiaoqun Dong · 6 shared papers, 2011–2012 · strength 0.20
  22. Deyali Chatterjee · 7 shared papers, 2012–2014 · strength 0.20
  23. Jean‐Nicolas Vauthey · 7 shared papers, 2012–2014 · strength 0.19
  24. Xuefeng Zhang · 2 shared papers, 2019 · strength 0.19
  25. Xinyuan Xu · 2 shared papers, 2019 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.